Press Releases

Date Title  
Toggle Summary Natera Launches Proposed Follow-On Offering
SAN CARLOS, Calif. , Sept. 9, 2020 /PRNewswire/ -- Natera, Inc . (Nasdaq: NTRA), a global leader in cell-free DNA testing, today announced the launch of a proposed follow-on public offering of $250,000,000 of shares of its common stock. In addition, Natera expects to grant the underwriters a 30-day
Toggle Summary Natera Receives Final Medicare Coverage for its Signatera™ MRD Test in Stage II-III Colorectal Cancer
Creates patient access to first-of-its-kind, personalized ctDNA test to inform adjuvant treatment decisions and detect recurrence earlier than standard diagnostic tools SAN CARLOS, Calif. , Sept. 3, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA
Toggle Summary SMART Study Data for Aneuploidy and 22q Unblinded
Natera extends NIPT technology leadership with new Panorama® artificial intelligence platform SAN CARLOS, Calif. , Sept. 2, 2020 /PRNewswire/ --  Natera, Inc. (NASDAQ: NTRA), a pioneer and leader in cell-free DNA testing, today announced the unblinding of the SMART clinical trial data, and the
Toggle Summary Study Shows Clinical Utility of the Prospera™ Test in Nephrology Practice
Nephrologists using the Prospera donor-derived cell-free DNA (dd-cfDNA) test were more likely to correctly diagnose rejection and take the appropriate action SAN CARLOS, Calif. , Sept. 1, 2020 /PRNewswire/ -- Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today
Toggle Summary Natera Announces Collaboration with Massachusetts General Hospital for a Prospective Randomized Clinical Trial in Early Stage Breast Cancer
Study to use Signatera™ to test effectiveness of Ribociclib in combination with endocrine therapy versus standard endocrine therapy SAN CARLOS, Calif. , Aug. 27, 2020 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA, today announced a collaborative
Toggle Summary Natera's Signatera™ Test Receives CE Mark
Supports clinical use and implementation of global clinical trials SAN CARLOS, Calif. , Aug. 26, 2020 /PRNewswire/ -- Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that it has received the CE mark for the Signatera test, a personalized,
Toggle Summary Joint Guideline from ACOG and SMFM Supports use of Non-Invasive Prenatal Testing (NIPT) for all Pregnant Women
SAN CARLOS, Calif. , Aug. 18, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA) , a leader in non-invasive prenatal testing, announced a joint guideline released yesterday by the American College of Obstetrics and Gynecology (ACOG) and Society of Maternal Fetal Medicine (SMFM), regarding the use of
Toggle Summary Natera Files Additional Suit Against ArcherDX
SAN CARLOS, Calif. , Aug. 7, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, filed suit yesterday against ArcherDX, Inc. for infringement of Natera's U.S. Patent No. 10,731,220 (the "'220 Patent"). The complaint was filed in the U.S.
Toggle Summary Natera Reports Second Quarter 2020 Financial Results
SAN CARLOS, Calif. , Aug. 5, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ:  NTRA), a pioneer and global leader in cell-free DNA testing, today reported financial results for the second quarter ended June 30, 2020 and provided an update on recent business progress.
Toggle Summary New Publication in Nature Cancer Demonstrates Signatera's Ability to Evaluate Tumor Response to Immunotherapy
Prospective phase II study shows personalized ctDNA analysis may be used as a biomarker of efficacy across a broad range of tumor types SAN CARLOS, Calif. , Aug. 3, 2020 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced the

Footer disclaimer

Footer disclaimer

© Natera 2020. All Rights Reserved. The tests described on this site were developed by Natera, Inc. a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). The tests have not been cleared or approved by the U.S. Food and Drug Administration (FDA). Although FDA does not currently clear or approve laboratory-developed tests in the U.S., certification of the laboratory is required under CLIA to ensure the quality and validity of the tests.